Cliff Asness's ZNTL Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 45,995 shares of Zentalis Pharmaceuticals, Inc. (ZNTL) worth $62,093, representing 0.00% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in ZNTL, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 396,233 shares. Largest reduction occurred in Q3 2025, reducing 327,993 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Zentalis Pharmaceuticals (ZNTL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Zentalis Pharmaceuticals (ZNTL) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -60,970 | Reduce 57.00% | 45,995 | $1.35 |
| Q3 2025 | -327,993 | Reduce 75.41% | 106,965 | $1.51 |
| Q2 2025 | -184,372 | Reduce 29.77% | 434,958 | $1.16 |
| Q1 2025 | +396,233 | Add 177.61% | 619,330 | $1.59 |
| Q4 2024 | +27,615 | Add 14.13% | 223,097 | $3.03 |
| Q3 2024 | +195,482 | New Buy | 195,482 | $3.68 |
| Q2 2022 | -4,517 | Sold Out | 0 | $0.00 |
| Q1 2022 | -2,725 | Reduce 37.63% | 4,517 | $46.05 |
| Q4 2021 | +7,242 | New Buy | 7,242 | $84.09 |
Cliff Asness's Zentalis Pharmaceuticals Investment FAQs
Cliff Asness first purchased Zentalis Pharmaceuticals, Inc. (ZNTL) in Q4 2021, acquiring 7,242 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Zentalis Pharmaceuticals, Inc. (ZNTL) for 9 quarters since Q4 2021.
Cliff Asness's largest addition to Zentalis Pharmaceuticals, Inc. (ZNTL) was in Q1 2025, adding 619,330 shares worth $984,734.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 45,995 shares of Zentalis Pharmaceuticals, Inc. (ZNTL), valued at approximately $62,093.
As of the Q4 2025 filing, Zentalis Pharmaceuticals, Inc. (ZNTL) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Zentalis Pharmaceuticals, Inc. (ZNTL) was 619,330 shares, as reported at the end of Q1 2025.